Novo Nordisk conducts a two-for-one stock split

Bagsværd, Denmark, 13 September 2023 – As communicated on 10 August 2023 in connection with the release of Novo Nordisk’s financial results for the first six months of 2023, Novo Nordisk’s Board of Directors has approved a split of the trading units of the Novo Nordisk B shares listed on Nasdaq Copenhagen and of the American Depositary Receipts (ADRs) listed on New York Stock Exchange (NYSE) in a two-for-one ratio.

Novo Nordisk’s B shares have been listed on Nasdaq Copenhagen in trading units of DKK 0.20 and its American Depositary Receipts (ADRs) that equal B-shares of DKK 0.20 have been listed on New York Stock Exchange (NYSE).

Consequently, the trading unit of the Novo Nordisk B shares listed on Nasdaq Copenhagen has been changed from DKK 0.20 to DKK 0.10 as of 13 September 2023. The ADRs will similarly be split as of 20 September 2023 to maintain the one-to-one relationship between the B-share and the ADR.

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 59,000 people in 80 countries and markets its products in around 170 countries. For more information, visit, Facebook, Instagram, X, LinkedIn and YouTube.

Contacts for further information

Ambre James-Brown
+45 3079 9289
Elizabeth DeLuca (US)
+1 609 580 9868
Daniel Muusmann Bohsen
+45 3075 2175
Jacob Martin Wiborg Rode
+45 3075 5956
David Heiberg Landsted
+45 3077 6915
Mark Joseph Root (US)
+1 848 213 3219
Sina Meyer
+45 3075 6656
Frederik Taylor Pitter
+45 3075 8259


error: Content is protected !!